A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

Progression-Free Survival (PFS) as assessed by BIRC for Arm B versus Arm D

PFS is defined as the time from randomization to the date of progression or death, whichever occurs first.

Time frame: Up to approximately 69 months

Rate of uMRD4 for Arm A versus Arm D

The rate of undetectable minimal residual disease (uMRD4) in peripheral blood based on next-generation sequencing (NGS)

Time frame: Up to approximately 12 months

Complete Response Rate as assessed by BIRC for Arm A versus Arm D

Complete Response Rate (CRR) is defined as the percentage of participants that achieve a best response of complete response (CR) or complete response with incomplete hematopoietic recovery (CRi)

Time frame: Up to approximately 25 months

Overall Survival for Arm A versus Arm D

Overall survival (OS) is defined as the time from the date of randomization to the date of death

Time frame: Up to approximately 84 months

PFS per Investigator Assessment (INV) for Arm B versus Arm D

PFS is defined as the time from randomization to the date of progression or death, whichever occurs first.

Time frame: Up to approximately 69 months

CRR per BIRC and by INV for Arm B versus Arm D

CRR is defined as the percentage of participants that achieve a best response of CR or CRi

Time frame: Up to approximately 25 months

OS for Arm B versus Arm D

OS is defined as the time from the date of randomization to the date of death

Time frame: Up to approximately 84 months

Rate of uMRD4 for Arm B versus Arm D

The rate of uMRD4 in peripheral blood based on NGS

Time frame: Up to approximately 25 months

PFS per BIRC and by INV for Arm A versus Arm B

PFS is defined as the time from randomization to the date of progression or death, whichever occurs first.

Time frame: Up to approximately 69 months

CRR per BIRC and by INV for Arm A versus Arm B

CRR is defined as the percentage of participants that achieve a best response of CR or CRi

Time frame: Up to approximately 25 months

OS for Arm A versus Arm B

OS is defined as the time from the date of randomization to the date of death

Time frame: Up to approximately 84 months

Rate of uMRD4 for Arm A versus Arm B

The rate of uMRD4 in peripheral blood based on NGS

Time frame: Up to approximately 25 months

Rate of uMRD4 for Arm A versus Arm D

The rate of uMRD4 in peripheral blood based on NGS

Time frame: Up to approximately 25 months

CRR per INV for Arm A versus Arm D

CRR is defined as the percentage of participants that achieve a best response of CR or CRi

Time frame: Up to approximately 25 months

PFS per INV for Arm A versus Arm D

PFS is defined as the time from randomization to the date of progression or death, whichever occurs first.

Time frame: Up to approximately 51 months

PFS per INV for Arm C versus Arm D

PFS is defined as the time from randomization to the date of progression or death, whichever occurs first.

Time frame: Up to approximately 69 months

CRR per INV for Arm C versus Arm D

CRR is defined as the percentage of participants that achieve a best response of CR or CRi

Time frame: Up to approximately 25 months

OS for Arm C versus Arm D

OS is defined as the time from the date of randomization to the date of death

Time frame: Up to approximately 84 months

Rate of uMRD4 for Arm C versus Arm D

The rate of uMRD4 in peripheral blood based on NGS

Time frame: Up to approximately 25 months

Overall Response Rate (ORR) per BIRC and by INV

ORR is defined as the percentage of participants that achieve a best response of partial response (PR) or better

Time frame: Up to approximately 25 months

Duration of Response (DOR) per BIRC and by INV

DOR is defined as the time from the date that response criteria were first met to the date of first documentation of disease progression or death, whichever occurs first

Time frame: Up to approximately 69 months

Time to Response (TTR) per BIRC and by INV

TTR is defined as the time from the date of randomization to the date response criteria were first met

Time frame: Up to approximately 25 months

Time to Next Anti-CLL/SLL Treatment (TTNT)

TTNT is defined as the time from the date of randomization to the date of next anti-CLL/SLL treatment

Time frame: Up to approximately 84 months

Rate of uMRD4

The rate of uMRD4 in peripheral blood based on NGS

Time frame: Up to approximately 25 months

Change from Baseline in the European Organisation of Research and Treatment of Cancer-Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30) Global Health Status/Quality of Life and Physical Functioning Scales

The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 =Not at all (best) to 4 =Very Much (worst) and 2 questions answered on a 7-point scale where 1 =Very poor (worst) to 7 =Excellent (best). Higher scores in global health status (GHS) and functional scales indicate better health-related quality of life (HRQoL).

Time frame: Baseline and up to approximately 69 months

Change from Baseline in EORTC QLQ for Chronic Lymphocytic Leukemia (EORTC QLQ-CLL17) Symptom Burden and Fatigue Scales

The EORTC QLQ-CLL17 is the CLL module of QLQ-C30 consisting of 17 items and comprising 3 scales: symptom burden due to disease and/or treatment (6 items), physical condition/fatigue (4 items), and worries/fears about health and functioning (7 items) Items are rated using a 4-point response scale ("not at all," "a little," "quite a bit," and "very much") and the recall period for all items is the past 7 days. Lower scores indicate better HRQoL.

Time frame: Baseline and up to approximately 69 months

Number of Participants with Treatment-Emergent Adverse Events (TEAEs)

Number of participants with TEAEs, including laboratory values, vital signs, and physical examination findings, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0.

Time frame: From the first dose of study drug(s) to 30 days after the last dose of sonrotoclax or venetoclax, or 90 days after the last dose of obinutuzumab or rituximab; up to approximately 26 months